Eletriptan

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 12, 2009, Pages 1587-1598

  Sandrini, Giorgio ^a,b   Perrotta, Armando ^c   Tassorelli, Cristina ^a,b   Nappi, Giuseppe ^a,b,d  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b University Centre for Adaptive Disorders and Headache   (Italy)

^c IRCCS NEUROMED   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Eletriptan; Migraine; Serotonin agonists; Triptans

Indexed keywords

ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; ALMOTRIPTAN; CAFFEINE; CLARITHROMYCIN; ELETRIPTAN; ERGOTAMINE; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NARATRIPTAN; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROPRANOLOL; RITONAVIR; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; VERAPAMIL; ZOLMITRIPTAN;

ASTHENIA; CHEST TIGHTNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NEUROTRANSMISSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROTONIN SYNDROME; SOMNOLENCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; MIGRAINE DISORDERS; PYRROLIDINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 71049154907     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903410226     Document Type: Review

References (71)

1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
2. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45(Suppl 1):S3-13
3. Stovner LJ, Zwart JA, Hagen K, et al. Epidemiology of headache in Europe [review]. Eur J Neurol 2006;13(4):333-345
4. Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27(3):193-210
5. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Incidence of primary headache: a Danish epidemiologic follow-up study. Am J Epidemiol 2005;161(11):1066-1073
6. Tfelt-Hansen P. Acute pharmacotherapy of migraine, tension-type headache, and cluster headache. J Headache Pain 2007;8:127-134
7. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62(5):509-525
8. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89(2-3):107-110
9. Dodick D, Liptonl RB, Martin V, et al. The Triptan Cardiovascular Safety Expert Panel, Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004;44:414-425
10. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(6):754-762
11. British National Formulary, edition 58; 2009. Accessed October 2009.
12. US Product Information for Relpax. Available from: http://media.pfizer. com/files/products/uspi-relpax.pdf. [Last accessed October 2009]
13. Napier C, Stewart M, Melrose H, et al. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999;368(2-3):259-268
14. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60(6):1259-1287
15. Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40(3):189-205
16. Ottervanger JP, van Witsen TB, Valkenburg HA, et al. Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol 1994;47:305-309
17. MaassenVanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000;55(10):1524-1530
18. Gupta P, Butler P, Shepperson NB, McHarg A. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist. Eur J Pharmacol 2000;398(1):73-81
19. Muir DF, McCann GP, Swan L, et al. Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Clin Pharmacol Ther 1999;66(1):85-90
20. Goldstein JA, Massey KD, Kirby S, et al. Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia 2004;24(7):515-521
21. Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008;9:5-12
22. Knyihar-Csillik E, Tajti J, Csillik AE, et al. Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci 2000;12(11):3991-4002
23. Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain 1999;82(1):15-22
24. Lambert GA, Boers PM, Hoskin KL, et al. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res 2002;953(1-2):181-188
25. Hoskin KL, Lambert GA, Donaldson C, Zagami AS. The 5-hydroxytryptamine1B/ 1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res 2004;998(1):91-99
26. Milton KA, Scott NR, Allen MJ, et al. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT 1B/1D agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 2002;42:528-539
27. Shah AK, Harris SC, Greenhalgh C, Morganroth J. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol 2002;42:520-527
28. Evans DC, O'Connor D, Lake BG, et al. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003;31(7):861-869
29. Tepper S, Allen C, Sanders D, et al. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 2003;43(1):44-8. Erratum in: Headache 2003;43(7):833
30. Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: a comparative review [review]. J Clin Pharmacol 2000;40(7):687-700
31. Shah AK, Laboy-Goral L, Scott N, et al. Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. J Clin Pharmacol 2001;41(12):1339-1344
32. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97(3):247-257
33. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358(9294):1668-1675
34. Tfelt-Hansen P. A review of evidence-based medicine and meta-analytic reviews in migraine [review]. Cephalalgia 2006;26(11):1265-1274
35. Stark R, Dahlof C, Haughie S, Hettiarachchi J; Eletriptan Steering Committee. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002;22(1):23-32
36. Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002;22(6):416-423
37. Sheftell F, Ryan R, Pitman V; Eletriptan Steering Committee. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003;43(3):202-213
38. Färkkilä M, Olesen J, Dahlöf C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:198-203
39. Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics 2000;18(6):557-566
40. Salonen R, Kori S, Scott A, Richardson MS. Encapsulated sumatriptan is not bioequivalent to commercial sumatriptan. Headache 2003;43(8):923-924
41. Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain-results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 2005;25(9):715-725
42. Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability [review]. Headache 2007;47(8):1152-1168
43. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000;54(1):156-163
44. Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003;43(3):214-222, (a)
45. Sandrini G, Farkkila M, Burgess G, et al.; Eletriptan Steering Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002;59(8):1210-1217
46. Diener HC, Ryan R, Sun W, Hettiarachchi J. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol 2005;11(2):125-134
47. Schoenen J, Pascual J, Rasmussen S, et al. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Eur J Neurol 2005;12(2):108-117
48. Vollono C, Capuano A, Mei D, et al. Multiple attack study on the available triptans in Italy versus placebo. Eur J Neurol 2005;12(7):557-563
49. Steiner TJ, Diener HC, MacGregor EA, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003;23:942-952
50. Garcia-Ramos G, MacGregor EA, Hilliard B, et al. Comparative efficacy of eletriptan versus naratriptan in the acute treatment of migraine. Cephalalgia 2003;23:869-876
51. Lainez MJ, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006;26(3):246-256
52. Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot® ) in the acute treatment of migraine: a multicentre, randomized, double-blind, placebo-controlled comparison. Eur Neurol 2002;47(2):99-107
53. Chia Y-C, Lim S-H, Wang S-J, et al. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatories. Headache 2003;43:984-990
54. Martin VT, Loder E, Taylor K, et al. Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study. Cephalalgia 2005;25(9):726-734
55. Diamond ML, Hettiarachchi J, Hilliard B, et al. Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 2004;44(3):209-216
56. Goldstein J, Tiseo P, Denaro J, Sikes C. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006;46(7):1142-1150
57. Pascual J. Clinical benefits of early triptan therapy for migraine. Headache 2002;42(Suppl 1):S10-17
58. Brandes JL, Kudrow D, Cady R, et al. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005;25:735-742
59. Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003;43(9):962-974, (b)
60. Newman CM, Starkey I, Buller N, et al. Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries. Eur J Clin Pharmacol 2005;61(10):733-742
61. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the US: disability and economic costs. Arch Intern Med 1999;159:813-818
62. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290(18):2443-2454
63. Perfetto EM, Weis KA, Mullins CD, et al. An economic evaluation of triptan products for migraine. Value Health 2005;8(6):647-655
64. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 1994;309:765-769
65. Winner P, Rothner AD, editors, Headache in children and adolescents. Hamilton, Canada, BC Decker Inc; 2001
66. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in paediatric migraine: characterization of age-related effects using PedsQL 4.0. Cephalalgia 2004;24:120-127
67. Wöber-Bingöl Ç, Wöber C, Karwautz A, et al. Clinical features of migraine: a cross-sectional study in patients aged three to sixty-nine. Cephalalgia 2004;24:12-17
68. Hershey AD, Winner P, Kabbouche MA, et al. Use of the ICHD-II criteria in the diagnosis of pediatric migraine. Headache 2005;45:1288-1297
69. Damen L, Bruijn JK, Verhagen AP, et al. Symptomatic treatment of migraine in children: a systematic review of medication trials [review]. Pediatrics 2005;116(2):e295-302
70. Winner P, Linder SL, Lipton RB, et al. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache 2007;47(4):511-518
71. Zebenholzer K, Wober C, Vigl M, Wessely P. Eletriptan for the short-term prophylaxis of cluster headache. Headache 2004;44(4):361-364